Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Alpha Interferon: A New Treatment for AIDS-Related Kaposi's Sarcoma

Alpha Interferon: A New Treatment for AIDS-Related Kaposi's Sarcoma A New Treatment for Alpha Interferon: AIDS-Related Kaposi's Sarcoma FDA Approves Marketing of Two Drugs tumor activity. While tumor regressions have been seen in between 20 and 67 percent of the patients, scientists have not known whether the results reflect an anti-tumor effect alone, whether alpha interferon acts by boosting the immune system, or whether the drug acts against HTV itself.10 By Carole Moussalli new drugs based on alpha inferieron recombinant technology are now available for patients with AIDS-related Kaposi's sarcoma: Intron-A (Schering-Plough) and Roferon-A (Roche). The marketing approval granted by the FDA was based partly on results from clinical studies showing that alpha inferieron can reduce the severity of lesions and prolong the lives of patients Two measles and chicken pox, at the time. Interferon was the proposed explanation. Since then, interferon research has progressed steadily. It is now being investigated worldwide for the treatment of many cancers and viral disas such same eases. Discovered in Europe Classical Kaposi's Sarcoma Lane and his colleagues at NIAID, found that the drug is most effective in those patients whose immune systems are less damaged by infection with HTV.6 Patients who experience the most beneficial effects of high doses of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png AIDS Patient Care Mary Ann Liebert

Alpha Interferon: A New Treatment for AIDS-Related Kaposi's Sarcoma

AIDS Patient Care , Volume 3 (3) – Jun 1, 1989

Alpha Interferon: A New Treatment for AIDS-Related Kaposi's Sarcoma

AIDS Patient Care , Volume 3 (3) – Jun 1, 1989

Abstract

A New Treatment for Alpha Interferon: AIDS-Related Kaposi's Sarcoma FDA Approves Marketing of Two Drugs tumor activity. While tumor regressions have been seen in between 20 and 67 percent of the patients, scientists have not known whether the results reflect an anti-tumor effect alone, whether alpha interferon acts by boosting the immune system, or whether the drug acts against HTV itself.10 By Carole Moussalli new drugs based on alpha inferieron recombinant technology are now available for patients with AIDS-related Kaposi's sarcoma: Intron-A (Schering-Plough) and Roferon-A (Roche). The marketing approval granted by the FDA was based partly on results from clinical studies showing that alpha inferieron can reduce the severity of lesions and prolong the lives of patients Two measles and chicken pox, at the time. Interferon was the proposed explanation. Since then, interferon research has progressed steadily. It is now being investigated worldwide for the treatment of many cancers and viral disas such same eases. Discovered in Europe Classical Kaposi's Sarcoma Lane and his colleagues at NIAID, found that the drug is most effective in those patients whose immune systems are less damaged by infection with HTV.6 Patients who experience the most beneficial effects of high doses of

Loading next page...
 
/lp/mary-ann-liebert/alpha-interferon-a-new-treatment-for-aids-related-kaposi-s-sarcoma-seIDcwS5FA
Publisher
Mary Ann Liebert
Copyright
Copyright 1989 Mary Ann Liebert, Inc.
ISSN
0893-5068
eISSN
1557-7449
DOI
10.1089/apc.1989.3.16
Publisher site
See Article on Publisher Site

Abstract

A New Treatment for Alpha Interferon: AIDS-Related Kaposi's Sarcoma FDA Approves Marketing of Two Drugs tumor activity. While tumor regressions have been seen in between 20 and 67 percent of the patients, scientists have not known whether the results reflect an anti-tumor effect alone, whether alpha interferon acts by boosting the immune system, or whether the drug acts against HTV itself.10 By Carole Moussalli new drugs based on alpha inferieron recombinant technology are now available for patients with AIDS-related Kaposi's sarcoma: Intron-A (Schering-Plough) and Roferon-A (Roche). The marketing approval granted by the FDA was based partly on results from clinical studies showing that alpha inferieron can reduce the severity of lesions and prolong the lives of patients Two measles and chicken pox, at the time. Interferon was the proposed explanation. Since then, interferon research has progressed steadily. It is now being investigated worldwide for the treatment of many cancers and viral disas such same eases. Discovered in Europe Classical Kaposi's Sarcoma Lane and his colleagues at NIAID, found that the drug is most effective in those patients whose immune systems are less damaged by infection with HTV.6 Patients who experience the most beneficial effects of high doses of

Journal

AIDS Patient CareMary Ann Liebert

Published: Jun 1, 1989

There are no references for this article.